Immunization of monkeys with yellow fever virus-specified nonstructural protein NS1 resulted in protection against fatal hepatitis as well as marked reduction in the magnitude of virema after subcutaneous challenge with yellow fever virus. The results may be relevant to the design of possible subunit or recombinant flavivirus vaccines.
The virus-specified nonstructural protein gp48, currently designated NS1 (7), is highly conserved among flaviviruses. It is expressed on the surfaces of infected cells and is probably the complement-fixing (CF) antigen (1, 10) . We and others have recently shown that monoclonal antibodies to NS1 of the 17D vaccine strain of yellow fever virus (17D YF) confer passive protection in mice against lethal intracerebral challenge with 17D YF (6, 9) . The protective capacity of monoclonal antibodies to NS1 correlated with their CF activity and with their ability to lyse virus-infected cells (9) . It was further shown that active immunization with NS1 conferred solid protection in the absence of detectable neutralizing or other anti-virion antibodies. Because these findings may be relevant to the design of possible subunit or recombinant flavivirus vaccines, we extended our studies to immunization of monkeys against subcutaneous challenge with wild YF. Protection in monkeys against the wild strain of YF has previously been accomplished only by immunization with live-virus vaccines.
Domestic rhesus monkeys (6 to 10 kg) were prescreened for the absence of anti-flavivirus antibody by hemagglutination inhibition and complement fixation testing against dengue (serotypes 1 through 4), St. Louis encephalitis, Japanese encephalitis viruses, and YF and by neutralization assay against YF. Immunoaffinity-purified NS1 was prepared from lysates of 17D YF-infected Vero cells as previously described (9) . Five rhesus monkeys were given combined intradermal and subcutaneous injections of NS1 adsorbed to an alum adjuvant (Alhydrogel; Accurate Chemical and Scientific Corp., Westbury, N.Y.). Four monkeys injected in parallel with ovalbumin in alum served as controls. Animals were injected initially with 100 ,ug and given booster injections of 50 ,ug of NS1 or ovalbumin at 3 and at 7 weeks; they were challenged 1 to 2 weeks after the second booster injection by subcutaneous inoculation of a lethal dose (375 to 700 PFU) of African strain Dakar 1279 YF. Subcutaneous inoculation of 50 to 200 PFU of this virus is uniformly lethal for rhesus monkeys. Serum anti-NS1 antibody responses were measured by an enzyme-linked immunoassay (9) with a goat anti-monkey immunoglobulin G detector and by a standard complement fixation assay (2) . Anti-virion antibody was measured by plaque reduction neutralization assay of Dakar 1279 YF in Vero cells in the presence of fresh frozen human plasma (3, 5) and by conventional hemagglutination * Corresponding author. inhibition assay (4) . The viral protein specificity of immune serum was determined by radioimmunoprecipitation and sodium dodecyl sulphate-polyacrylamide gel electrophoresis by using previously described methods (8) .
There were no apparent ill effects of hyperimmunization with NS1. High-titer (1:1,000 to 1:10,000) anti-NS1 antibody was detected by enzyme-linked immunoassay within 2 weeks of the initial injection and reached sustained high levels (1:40,000 to 1:300,000) after the first booster injection in all NS1-immunized monkeys, with marginal or no increase after the second booster injection. Sera from control monkeys were uniformly negative (<1:10) by enzyme-linked immunoassay. Changes in anti-NS1 antibody titer were paralleled by changes in CF antibody levels. CF and neutralizing antibody titers are shown (Table 1) . Serum from control monkey X673 was slightly anti-complementary. Of the five NS1-immunized monkeys, three had no detectable neutralizing antibody (no plaque reduction in Vero cells at 1:2 dilution), but neutralization (90% plaque reduction) was observed at a 1:32 dilution of the prechallenge serum of monkeys 15 and 503C. No hemagglutination inhibition activity (<1:10) was detected in any of the prechallenge sera. Sera taken immediately prechallenge with YF gave strong precipitin bands with NS1 as determined by radioimmunoprecipitation and polyacrylamide gel electrophoresis (Fig. 1) . The fainter precipitin bands with E protein that were observed are similar to those previously noted with monoclonal antibodies to NS1 (8) and with the 8G4 antibody to NS1 on the same gel.
A consistent pattern of high-grade viremia and evolution of clinical signs followed infection of the control monkeys. Fever appeared by postchallenge day 3 followed by listlessness, progressive jaundice, hemorrhage, striking elevations of serum glutamic pyruvic transaminase levels (2,170 to 7,960 U/ml; normal range, 5 to 45 U/ml), and prolonged prothrombin times (26 to 60 s; normal, 11 to 16 s). All four control monkeys died, as expected, whereas four of the five immunized monkeys survived (P < 0.04, Fisher's exact test). Death occurred on day 5 or 6, and massive liver necrosis was found at autopsy. Of the surviving monkeys, monkey 15 had no detectable viremia and apart from a transient slight increase in serum glutamic pyruvic transaminase level (62 U/ml) did not exhibit any clinically apparent disease. Similar degrees of mild illness with fever, poor feeding, and evidence of hepatitis as determined by slight elevations of serum glutamic pyruvic transaminase 
